The FDA approved 50 novel drugs in 2024, including 18 biosimilars, with many targeting rare diseases and offering ...

Numab Therapeutics raises $55 million to advance its multi-specific antibody pipeline targeting inflammation and oncology, ...

USA-based Climb Bio said yesterday it has entered into an exclusive license agreement with Beijing Mabworks Biotech for ...

UCB partners with Ailux Biologics to use XtalPi's AI-driven XtalFold platform for antibody discovery and optimization. The ...

German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as ...

German family-owned pharma major Boehringer Ingelheim has licensed antibody-drug conjugates ADC technology from ...

Sanofi reports positive Phase III results for a subcutaneous version of Sarclisa in relapsed or refractory multiple myeloma.

Spanish firm Grifols has submitted a Biologics License Application (BLA) for its new potential fibrinogen treatment to the US ...

MitoRx Therapeutics strengthens its leadership with the appointments of Lubor Gaal as chief business officer and Stacey ...

Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to ...

Swiss oncology-focused Araris Biotech developing next-generation antibody drug conjugates (ADCs), today announced a research ...

The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) ...